HomeRamelteon

Ramelteon

Also known as: Ramelteon

Melatonin Receptor AgonistMelatonin Receptor Agonists

Route: Oral

Check Ramelteon Interactions →
10 interactions on record

Ramelteon has 10 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Alcohol, Fluvoxamine, Rifampin. Patients taking Ramelteon should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
10
Contraindicated
2
Major
1
Moderate
5

Contraindicated (2)

  • Ramelteon + AlcoholCauses additive psychomotor impairment. Should not be used in combination with ramelteon.
  • Ramelteon + FluvoxamineStrong CYP1A2 inhibitor that increases ramelteon AUC approximately 190-fold and Cmax approximately 70-fold; should not b

Major (1)

  • Ramelteon + RifampinStrong CYP enzyme inducer causing approximately 80% decrease in ramelteon exposure and metabolite M-II. Efficacy may be

Moderate (5)

  • Ramelteon + DeferasiroxDeferasirox inhibits CYP1A2 resulting in increased ramelteon concentration. Monitor for exposure related toxicity.
  • Ramelteon + DonepezilIncreases ramelteon AUC by approximately 100% and Cmax by 87%; patients should be closely monitored.
  • Ramelteon + DoxepinIncreases ramelteon AUC by approximately 66% and Cmax by 69%; patients should be closely monitored.
  • Ramelteon + Fluconazole( 7.1 ) Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. Flucon
  • Ramelteon + Ketoconazole( 7.1 ) Ketoconazole (strong CYP3A4 inhibitor): Increases AUC for ramelteon; administer with caution. Ketoconazole (stro
Ramelteon + Omeprazoleℹ️Unknown

Interaction studies of concomitant administration of ramelteon with fluoxetine (CYP2D6 inhibitor), omeprazole (CYP1A2 inducer/CYP2C19 inhibitor), theophylline (CYP1A2 substrate), dextromethorphan (CYP2D6 substrate), sertraline, venlafaxine, escitalopram, gabapentin, and zolpidem did not produce clinically meaningful changes in either peak or total exposures to ramelteon or the M-II metabolite. Concomitant administration of ramelteon with omeprazole (CYP2C19 substrate), dextromethorphan (CYP2D6 substrate), midazolam (CYP3A4 substrate), theophylline (CYP1A2 substrate), digoxin (p-glycoprotein substrate), warfarin (CYP2C9 [S]/CYP1A2 [R] substrate), venlafaxine, fluvoxamine, donepezil, doxepin, sertraline, escitalopram, and gabapentin did not produce clinically meaningful changes in peak and total exposures to these drugs.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.